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ABSTRACT
Introduction: Malignant melanoma of the gastrointestinal tract is usually a metastasis from a cutaneous source. Primary gastric melanoma is 
an extremely rare clinical entity, with few reported cases worldwide. It is often advanced at time of diagnosis and is associated with a dismal 
outcome.
Background: A 76 year old gentleman presenteded with a one month history of fatigue and exertional dyspnoea. Laboratory investigations 
indicated an anaemia, with a haemoglobin level of 11.0g/dl. Subsequent gastroscopy visualised a large, atypical, crater-like ulcerated lesion 
distal to the cardia in the proximal stomach.
Provisional histology was suggestive of a poorly differentiated adenocarcinoma but subsequent cyto-morphology and immunophenotyping 
were consistent with melanoma, with positive S100 protein, HMB45 and Melan A. Further molecular genetic testing revealed a V600R 
mutation in the BRAF gene, which is the first primary gastric melanoma with this mutation to be reported in the literature. Given the rarity of 
the findings, an extensive secondary work-up was undertaken, which concluded the diagnosis primary gastric melanoma.
Discussion: Primary gastric melanoma is a rare disease that can present similarly to other upper gastrointesinal lesions, with weight loss, 
abdominal pain, malena, and anaemia. Given its rarity, the pathogenesis is poorly understood. Lesions are often endoscopically atypical. 
Important points to note would include the absence of a primary lesion, as supported by a full skin examination and PET-CT findings, which 
can help to delineate the limitation to the stomach, thus helping to inform subsequent management.
LEARNING POINTS
• Primary gastric melanoma (PGM) is a rare clinical entity. 
• Work-up including skin and ophthalmic examination is important to exclude a primary cutaneous source, as this helps dictate both 
prognosis and subsequent management, including whether surgical resection is advisable. 
• Immunophenotyping and genetic testing inform management but, despite advances in therapy, the prognosis of PGM and other mucosal 
melanomas remains poor.
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INTRODUCTION
Primary gastric melanoma (PGM) is extremely rare, with few reported cases. PGM tends to metastasise early and has a poor outcome. We 
present the case of a patient whom an extensive work-up concluded PGM, with a rare BRAF V600R mutation. While BRAF mutations are 
common in cutaneous melanoma[1], they are rare in mucosal melanomas, and have not previously been described in a PGM.
CASE DESCRIPTION
A 76-year-old male patient presented with a one-month history of fatigue, exertional dyspnoea and weight loss. He had iron deficiency 
anaemia. At gastroscopy, there was a large ulcerated lesion in the proximal stomach (Fig. 1). Histological examination revealed extensive 
lamina propria infiltration by a population of large epithelioid malignant cells. Immunohistochemistry was positive for S100 Protein, HMB-
45, and Melan-A, consistent with malignant melanoma. Further genetic analysis revealed a V600R mutation at exon 15 of the BRAF gene. 
Work-up, including a full skin examination and ophthalmology review, did not identify another primary source, and no metastatic disease 
was identified on radiological imaging. The consensus diagnosis of the treating physicians and surgeons was that findings were consistent 
with PGM. Subsequently, he underwent an open sleeve gastrectomy, and histology confirmed a melanomatous process, with two positive 
local lymph nodes. 
Following post-operative recovery and prior to commencement of systemic treatment, a repeat CT scan of the thorax, abdomen and pelvis 
showed interval progression of the disease in the two-month interval, with new liver metastases and an enlarging left upper quadrant 
deposit. The patient commenced immunotherapy, but unfortunately died of disease progression within a few months.
Figure 1. Endoscopic image of a large ulcerated lesion in the 
proximal stomach
DISCUSSION
Melanoma is an aggressive neoplasm that usually occurs in cutaneous sites, but can also arise from other less common sites such as uveal 
tracts and mucosa. Mucosal melanoma accounts for only 1.3% of all these cases, tends to present with advanced disease, and generally has a 
very poor prognosis[2]. PGM, a subtype of mucosal melanoma, is an even rarer occurrence, with only sporadic case reports in the literature[3].
PGM presents similarly to other upper gastrointestinal lesions, with weight loss, abdominal pain, and melaena. If histology is diagnostic of 
melanoma, it is important to exclude metastasis from a primary cutaneous or ocular lesion, with full skin examination by a dermatologist 
and an ophthalmological assessment to outrule another primary source, as this influences both the prognosis and further management, 
including whether surgical resection is advisable. Detailed radiological imaging is performed to delineate the burden of metastases, if 
indicated by histology. 
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Genetic testing of melanoma is mandatory as it informs the treatment paradigm, with targeted therapies available for patients exhibiting 
specific mutations. Ninety per cent of all mutations are acquired, due to the effects of cumulative environmental factors, such as exposure 
to ultraviolet light. Mucosal melanomas have been found to exhibit different genetic mutations to their cutaneous counterparts, suggesting 
differing tumour biology[2]. Approximately 50% of cutaneous melanomas have a BRAF mutation[4], whereas BRAF mutations are rare in 
mucosal melanomas[1]. The BRAF oncogenic effect is exerted through increased activation of the MAP kinase pathway, leading to uncontrolled 
cell proliferation[5]. Several BRAF mutations have been described, with V600E accounting for over 80% of mutations[4]. The V600R mutation 
(a substitution of arginine for valine at codon 600 of the BRAF gene) was identified in this patient, and accounts for approximately 4% of all 
melanoma cases[6], and, to our knowledge, has not been previously described in a PGM.
There is no clear consensus on the management of PGM. In this case, the disease progressed rapidly despite management with surgery and 
immunotherapy, consistent with the scanty literature which suggests a uniformly poor prognosis.
